Human Immunodeficiency Virus type-1 (HIV-1) evades antibody-dependent phagocytosis

PLoS Pathogens

Volumn 13, Issue 12, 2017, Pages

  Gach, Johannes S ^a   Bouzin, Margaux ^b,c   Wong, Marcus P ^a   Chromikova, Veronika ^d   Gorlani, Andrea ^a   Yu, Kuan Ting ^a   Sharma, Brijesh ^a   Gratton, Enrico ^b,c   Forthal, Donald N ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California at Irvine   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; GLYCAN; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY; PHOSPHATIDYLSERINE; RNA 18S; GP41 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ARTICLE; CD4+ T LYMPHOCYTE; CELL LINE; CENTRIFUGATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE SPECTROSCOPY; HEK293T CELL LINE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHAGOCYTOSIS; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; THP 1 CELL LINE; U-937 CELL LINE; VIRUS INFECTION; GENETICS; HEK293 CELL LINE; HOST PATHOGEN INTERACTION; IMMUNE EVASION; IMMUNOLOGY; PATHOGENICITY; VIROLOGY; VIRUS ENTRY;

ANTIBODIES, MONOCLONAL; CELL LINE; HEK293 CELLS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; PHAGOCYTOSIS; U937 CELLS; VIRUS INTERNALIZATION;

EID: 85039922412     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006793     Document Type: Article

References (41)

1. Su B, Moog C, Which Antibody Functions are Important for an HIV Vaccine?Front Immunol. 2014;5:289. doi: 10.3389/fimmu.2014.00289 24995008.
2. Forthal DN, Functions of Antibodies. Microbiol Spectr. 2014;2(4):1–17. 25215264.
3. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275–86. doi: 10.1056/NEJMoa1113425 22475592.
4. Forthal DN, Gilbert PB, Landucci G, Phan T, Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol. 2007;178(10):6596–603. 17475891.
5. Fouts TR, Bagley K, Prado IJ, Bobb KL, Schwartz JA, Xu R, et al. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proc Natl Acad Sci U S A. 2015;112(9):E992–9. doi: 10.1073/pnas.1423669112 25681373.
6. Alpert MD, Harvey JD, Lauer WA, Reeves RK, Piatak M, Jr.Carville A, et al. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog. 2012;8(8):e1002890. doi: 10.1371/journal.ppat.1002890 22927823.
7. Kramski M, Parsons MS, Stratov I, Kent SJ, HIV-specific antibody immunity mediated through NK cells and monocytes. Curr HIV Res. 2013;11(5):388–406. 24191935.
8. Excler JL, Ake J, Robb ML, Kim JH, Plotkin SA, Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines. Clin Vaccine Immunol. 2014;21(8):1023–36. doi: 10.1128/CVI.00230-14 24920599.
9. Horner H, Frank C, Dechant C, Repp R, Glennie M, Herrmann M, et al. Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity. J Immunol. 2007;179(1):337–45. 17579054.
10. Daubeuf S, Lindorfer MA, Taylor RP, Joly E, Hudrisier D, The direction of plasma membrane exchange between lymphocytes and accessory cells by trogocytosis is influenced by the nature of the accessory cell. J Immunol. 2010;184(4):1897–908. doi: 10.4049/jimmunol.0901570 20089699.
11. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP, The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol. 2006;176(4):2600–9. 16456022.
12. Kramski M, Schorcht A, Johnston AP, Lichtfuss GF, Jegaskanda S, De Rose R, et al. Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity. J Immunol Methods. 2012;384(1–2):51–61. doi: 10.1016/j.jim.2012.07.006 22841577.
13. Hashimoto Y, Moki T, Takizawa T, Shiratsuchi A, Nakanishi Y, Evidence for phagocytosis of influenza virus-infected, apoptotic cells by neutrophils and macrophages in mice. J Immunol. 2007;178(4):2448–57. 17277152.
14. He W, Chen CJ, Mullarkey CE, Hamilton JR, Wong CK, Leon PE, et al. Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice. Nat Commun. 2017;8(1):846. doi: 10.1038/s41467-017-00928-3 29018261.
15. Quick ED, Leser JS, Clarke P, Tyler KL, Activation of intrinsic immune responses and microglial phagocytosis in an ex vivo spinal cord slice culture model of West Nile virus infection. J Virol. 2014;88(22):13005–14. doi: 10.1128/JVI.01994-14 25165111.
16. Flipse J, Diosa-Toro MA, Hoornweg TE, van de Pol DP, Urcuqui-Inchima S, Smit JM, Antibody-Dependent Enhancement of Dengue Virus Infection in Primary Human Macrophages; Balancing Higher Fusion against Antiviral Responses. Sci Rep. 2016;6:29201. doi: 10.1038/srep29201 27380892.
17. Forthal DN, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B, FcgammaRIIa genotype predicts progression of HIV infection. J Immunol. 2007;179(11):7916–23. 18025239.
18. Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods. 2011;366(1–2):8–19. doi: 10.1016/j.jim.2010.12.016 21192942.
19. Tay MZ, Liu P, Williams LD, McRaven MD, Sawant S, Gurley TC, et al. Antibody-mediated internalization of infectious HIV-1 virions differs among antibody isotypes and subclasses. PLoS Pathog. 2016;12(8):e1005817. doi: 10.1371/journal.ppat.1005817 27579713.
20. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009;5(5):e1000433. doi: 10.1371/journal.ppat.1000433 19436712.
21. Moody MA, Liao HX, Alam SM, Scearce RM, Plonk MK, Kozink DM, et al. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med. 2010;207(4):763–76. doi: 10.1084/jem.20091281 20368576.
22. Gach JS, Quendler H, Tong T, Narayan KM, Du SX, Whalen RG, et al. A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. PLoS One. 2013;8(8):e72054. doi: 10.1371/journal.pone.0072054 23991039.
23. Elson EL, Fluorescence correlation spectroscopy: past, present, future. Biophys J. 2011;101(12):2855–70. doi: 10.1016/j.bpj.2011.11.012 22208184.
24. Magde D, Elson EL, Webb WW, Fluorescence correlation spectroscopy. II. An experimental realization. Biopolymers. 1974;13(1):29–61. doi: 10.1002/bip.1974.360130103 4818131.
25. Elson EL, Magde D, Fluorescence correlation spectroscopy. I. Conceptual basis and theory. Biopolymers. 1974;13(1):1–27. doi: 10.1002/bip.1974.360130102
26. Lakowicz JR, Beechem JM, Gratton E, Fluorescence spectroscopy data analysis environment: A Second generation global analysis program. 1988;0909:70–81. doi: 10.1117/12.945370
27. Beechem JM, Gratton E, Ameloot M, Knutson JR, Brand L, The Global Analysis of Fluorescence Intensity and Anisotropy Decay Data: Second-Generation Theory and Programs. 2002;2:241–305. doi: 10.1007/0-306-47058-6_5
28. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326(5950):285–9. doi: 10.1126/science.1178746 19729618.
29. Zhu P, Liu J, Bess J, Jr.Chertova E, Lifson JD, Grise H, et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature. 2006;441(7095):847–52. doi: 10.1038/nature04817 16728975.
30. Ladinsky MS, Kieffer C, Olson G, Deruaz M, Vrbanac V, Tager AM, et al. Electron tomography of HIV-1 infection in gut-associated lymphoid tissue. PLoS Pathog. 2014;10(1):e1003899. doi: 10.1371/journal.ppat.1003899 24497830.
31. Kieffer C, Ladinsky MS, Ninh A, Galimidi RP, Bjorkman PJ, Longitudinal imaging of HIV-1 spread in humanized mice with parallel 3D immunofluorescence and electron tomography. Elife. 2017;6. doi: 10.7554/eLife.23282 28198699.
32. Magde D, Elson E, Webb WW, Thermodynamic fluctuations in a reacting system: measurement by fluorescence correlation spectroscopy. Phys Rev Lett. 1972;29:705–8. doi: 10.1103/PhysRevLett.29.705
33. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007;449(7158):101–4. doi: 10.1038/nature06106 17805298.
34. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV, Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014;158(6):1243–53. doi: 10.1016/j.cell.2014.08.023 25215485.
35. Fujisawa H, Neutrophils play an essential role in cooperation with antibody in both protection against and recovery from pulmonary infection with influenza virus in mice. J Virol. 2008;82(6):2772–83. doi: 10.1128/JVI.01210-07 18184718.
36. Vogt MR, Dowd KA, Engle M, Tesh RB, Johnson S, Pierson TC, et al. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms. J Virol. 2011;85(22):11567–80. doi: 10.1128/JVI.05859-11 21917960.
37. Lepock JR, Thompson JE, Kruuv J, Photoinduced crosslinking of membrane proteins by fluorescein isothiocyanate. Biochem Biophys Res Commun. 1978;85(1):344–50. 217376.
38. Leaman DP, Kinkead H, Zwick MB, In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. J Virol. 2010;84(7):3382–95. doi: 10.1128/JVI.02363-09 20089658.
39. Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, et al. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci U S A. 2013;110(1):E69–78. doi: 10.1073/pnas.1217609110 23237851.
40. Forthal DN, Landucci G, Phan TB, Becerra J, Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. J Virol. 2005;79(4):2042–9. doi: 10.1128/JVI.79.4.2042-2049.2005 15681406.
41. Smirnov A, Solga MD, Lannigan J, Criss AK, An improved method for differentiating cell-bound from internalized particles by imaging flow cytometry. J Immunol Methods. 2015;423:60–9. doi: 10.1016/j.jim.2015.04.028 25967947.